World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
140
Citations
91869
World Ranking
1666
National Ranking
965

Overview

Gilles Salles is affiliated with the Memorial Sloan Kettering Cancer Center in the United States. Their research primarily focuses on medicine with a strong emphasis on several subfields including pathology and forensic medicine, oncology, genetics, immunology, and molecular biology.

The scientist's work covers diverse topics related to lymphoma and cancer treatment. Key areas of study include lymphoma diagnosis and treatment, CAR-T cell therapy research, chronic lymphocytic leukemia research, viral-associated cancers and disorders, CNS lymphoma diagnosis and treatment, monoclonal and polyclonal antibodies research, and cancer genomics and diagnostics.

Selected recent publications by Gilles Salles include:

  • The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee, 2022, Blood
  • Diffuse Large B-Cell Lymphoma, 2021, New England Journal of Medicine
  • Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial, 2020, The Lancet
  • Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial, 2021, The Lancet Oncology
  • Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial, 2020, The Lancet Oncology

Co-authors frequently collaborating with Gilles Salles are Andrew D. Zelenetz, Lorenzo Falchi, Gunjan L. Shah, Miguel-Angel Perales, and Paul A. Hamlin.

The scientist has published extensively in a number of journals, with the highest volume of publications appearing in:

  • Blood
  • Hematological Oncology
  • Journal of Clinical Oncology
  • Clinical Lymphoma Myeloma & Leukemia
  • Blood Advances

Best Publications

  • The 2016 revision of the World Health Organization classification of lymphoid neoplasms

    Steven H. Swerdlow;Elias Campo;Stefano A. Pileri;Nancy Lee Harris

  • CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

    Bertrand Coiffier;Eric Lepage;Josette Briere;Raoul Herbrecht

  • Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Stephen J. Schuster;Michael R. Bishop;Constantine S. Tam;Edmund K. Waller

  • Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene

    Guillaume Cartron;Laurent Dacheux;Gilles Salles;Philippe Solal-Celigny

  • Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte

    P Feugier;A. Van Hoof;C. Sebban;P. Solal-Celigny

  • Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

    Gilles Salles;John Francis Seymour;Fritz Offner;Armando Lopez-Guillermo

  • PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

    Ajay K. Gopal;Ajay K. Gopal;Brad S. Kahl;Sven de Vos;Nina D. Wagner-Johnston

  • The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma

    Kerry J. Savage;Stefano Monti;Jeffery L. Kutok;Giorgio Cattoretti

  • Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response

    Stefano Monti;Kerry J. Savage;Jeffery L. Kutok;Friedrich Feuerhake

  • Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.

    Philippe Colombat;Gilles Salles;Nicole Brousse;Pitahey Eftekhari

  • Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed

    Catherine Thieblemont;Françoise Berger;Charles Dumontet;Isabelle Moullet

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    M Dreyling;M Ghielmini;S Rule;G Salles

  • Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte Study

    Corinne Haioun;Eric Lepage;Christian Gisselbrecht;Gilles Salles

  • Prognostic significance of survivin expression in diffuse large B-cell lymphomas

    Colette Adida;Corinne Haioun;Philippe Gaulard;Eric Lepage

  • Prognostic significance of bcl-2 protein expression in aggressive non- Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA)

    O Hermine;C Haioun;E Lepage;MF d'Agay

  • Diffuse Large B-Cell Lymphoma.

    Laurie H. Sehn;Gilles Salles

  • Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

    Gilles Salles;Martin Barrett;Robin Foà;Joerg Maurer

  • Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

    Franck Morschhauser;John Radford;Achiel Van Hoof;Umberto Vitolo

  • Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial

    Jeff P Sharman;Miklos Egyed;Wojciech Jurczak;Alan Skarbnik;Alan Skarbnik

Frequent Co-Authors

Hervé Tilly
Hervé Tilly University of Rouen
Corinne Haioun
Corinne Haioun Paris-Est Créteil University
Bertrand Coiffier
Bertrand Coiffier Centre Hospitalier Lyon Sud
Olivier Casasnovas
Olivier Casasnovas Grenoble Alpes University
Thierry Jo Molina
Thierry Jo Molina Université Paris Cité
Pier Luigi Zinzani
Pier Luigi Zinzani University of Bologna
Martin Dreyling
Martin Dreyling Ludwig-Maximilians-Universität München
Philippe Gaulard
Philippe Gaulard Université Paris Cité
Christopher R. Flowers
Christopher R. Flowers The University of Texas MD Anderson Cancer Center
Susan L. Slager
Susan L. Slager Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring options related to medicine in the USA, a variety of online degrees and career pathways can help you enter the healthcare field. For example, direct entry nurse practitioner programs for non-nurses online allow those with non-nursing backgrounds to quickly transition to advanced nursing roles, making healthcare careers more accessible than ever.

Many prospective students are concerned about admission requirements. Fortunately, there are nursing schools with high acceptance rates, which can increase your chance of starting a nursing career without the intense competition typically associated with medical programs.

Not everyone pursuing a healthcare career focuses on direct patient care. Administrative careers such as medical coding and billing are in high demand. You’ll find reputable medical billing and coding online schools that offer flexible programs, many with financial aid options available.

For those worried about standardized testing, a growing number of nursing schools that don't require teas test have simplified the admissions process—making it easier for more students to embark on nursing and healthcare careers.

Best Scientists Citing Gilles Salles

Trending Scientists

Recently Published Articles